Price movement over the last 24 hours
Abbott Laboratories vs Build A Bear Workshop Inc — how do they compare? Abbott Laboratories trades at $95.51 (market cap $166.94B), while Build A Bear Workshop Inc trades at $30.09 (market cap $388.91M). The key difference: Abbott Laboratories is far larger — about 429.3× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| ABT | BBW | |
|---|---|---|
Market Cap | $166.94B | $388.91M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $75.85 |
52-Week Low | $82.57 | $29.84 |
Enterprise Value | $193.69B | $488.35M |
Dividend Yield | 2.63% | 2.97% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Build-A-Bear Workshop (BBW) trades at $31.02, down 1.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics, including a P/E of 7.26 and a P/S of 0.76, alongside strong profitability with a net income margin of 10.48%. Recent developments include a CEO transition to Chris Hurt and the declaration of a $0.23 quarterly dividend payable in July 2026.
The long-term outlook is supported by a debt-free balance sheet, international expansion, and a 72.73% analyst buy rating with a $62.50 consensus price target, implying significant upside. Near-term risks include consumer spending pressures and revenue guidance reductions, but the fundamental setup remains attractive for recovery in the latter half of the year.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →